loader2
Login Open ICICI 3-in-1 Account
Text Size
Text to Speech
Color Contrast
Pause Animations

Panacea Biotec Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Panacea Biotec Ltd. 12 Feb 2026 12:36 PM

Q3FY26 Quarterly Result Announced for Panacea Biotec Ltd.

Biotechnology company Panacea Biotec announced Q3FY26 results

  • Revenue: Rs 16,519 lakh against Rs 16,349 lakh during Q3FY25, change 1%.
  • PBT: Rs 649 lakh against Rs 438 lakh during Q3FY25, change 48%.
  • PAT: Rs 389 lakh against Rs 444 lakh during Q3FY25, change -12%.
  • EPS: Rs 0.65 for Q3FY26.

Result PDF

Biotechnology company Panacea Biotec announced Q1FY25 results:

  • Panacea Biotec and ICMR Announce Phase III Clinical Trials for Tetravalent Dengue Vaccine, DengiALL
  • On the occasion of India's 78th Independence Day, Panacea Biotec Limited and the Indian Council of Medical Research (ICMR) are proud to announce the commencement of Phase III clinical trials for the tetravalent dengue candidate vaccine, DengiALL. The trials, approved by the Drugs Controller General of India (DCGI), will be conducted across 19 sites in India, involving 10,335 participants.
  • The journey of DengiALL began in 2006 at Panacea Biotec with the licensing and transfer of novel attenuated tetravalent dengue virus strains from the National Institutes of Health, USA. Phase I/II clinical trials were successfully conducted in the Indian population, with a comprehensive three-year safety follow-up completed in 2020. In March 2022, Panacea Biotec and ICMR signed an MoU to collaborate on Phase III clinical trials in India. 

On the occasion, Dr. Rajesh Jain, Chairman and Managing Director, at Panacea Biotec, said “DengiALL vaccine development has a long way since it was initiated in 2006 in collaboration with the National Institute of Health USA. We are excited to announce that our dengue vaccine candidate has successfully entered the penultimate Phase 3 clinical trials in India in collaboration with the Indian Council of Medical Research. This milestone brings us one step closer to providing a safe and effective solution for preventing dengue fever, a disease that poses a significant public health challenge. We are committed to ensuring that this vaccine meets the highest standards of safety and efficacy, and we are optimistic about its potential to make a meaningful impact on the lives of millions.”

Result PDF

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Get it on google Play Store Download on the App Store
market app